跳转至内容
Merck
CN

Y0001150

系统适用性试验用右丙氧芬

European Pharmacopoeia (EP) Reference Standard

别名:

右丙氧芬 盐酸盐

登录查看公司和协议定价

选择尺寸


关于此项目

经验公式(希尔记法):
C22H29NO2 · HCl
化学文摘社编号:
分子量:
375.93
UNSPSC代码:
41116107
NACRES:
NA.24
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

等级

pharmaceutical primary standard

API类

dextropropoxyphene

制造商/商品名称

EDQM

药品控制

regulated under CDSA - not available from Sigma-Aldrich Canada; estupefaciente (Spain); Decreto Lei 15/93: Tabela IA (Portugal)

应用

pharmaceutical (small molecule)

包装形式

neat

储存温度

2-8°C

SMILES字符串

[Cl-].N(C[C@H]([C@@](OC(=O)CC)(Cc2ccccc2)c1ccccc1)C)(C)C.[H+]

InChI

1S/C22H29NO2.ClH/c1-5-21(24)25-22(18(2)17-23(3)4,20-14-10-7-11-15-20)16-19-12-8-6-9-13-19;/h6-15,18H,5,16-17H2,1-4H3;1H/t18-,22+;/m1./s1

InChI key

QMQBBUPJKANITL-MYXGOWFTSA-N

正在寻找类似产品? 访问 产品对比指南

一般描述

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

应用

Dextropropoxyphene for system suitability EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

包装

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

其他说明

Sales restrictions may apply.

象形图

Skull and crossbones

警示用语:

Danger

危险声明

预防措施声明

危险分类

Acute Tox. 3 Oral

储存分类代码

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable

法规信息

监管及禁止进口产品

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助,请联系 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

India urged to reverse dextropropoxyphene ban.
Dinesh C Sharma
The Lancet. Oncology, 14(9), e344-e344 (2013-09-24)
Wayne A Ray et al.
Pharmacoepidemiology and drug safety, 22(4), 403-412 (2013-02-15)
The opioid analgesic propoxyphene was withdrawn from the US market in 2010, motivated by concerns regarding fatality in overdose and adverse cardiac effects, including prolongation of the QT interval. These concerns were based on case reports, summary vital statistics, and
Joseph L Schuller et al.
Expert opinion on pharmacotherapy, 13(13), 1825-1827 (2012-07-10)
The most commonly prescribed class of medications in the United States for chronic severe pain is opioid analgesics. Due to their low cost and widespread availability, the synthetic opioids are popular choices among clinicians and patients. However, there is an
Feng-Sheng Lin et al.
Acta anaesthesiologica Taiwanica : official journal of the Taiwan Society of Anesthesiologists, 50(2), 49-53 (2012-07-10)
Weak opioid combined with acetaminophen (APAP) has been proven to provide better analgesic efficacy and cause fewer complications than either drug alone. However, there are questions about whether different opioids, tramadol and propoxyphene, provide similar efficacy or safety. Thus, we
Cindy Bourne et al.
British journal of clinical pharmacology, 75(4), 1063-1067 (2012-09-05)
The risk of hypoglycaemia with tramadol (TRM) is not well described. Our aim was to analyze spontaneous reports of hypoglycaemia registered in the French Pharmacovigilance database and to compare these data with two other step-2 analgesic drugs. Cases of hypoglycaemia

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持